Rajat Rohatgi
Academic Appointments
- Assistant Professor, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute
- Assistant Professor (By courtesy), Biochemistry
Key Documents
Contact Information
-
Clinical Offices
Oncology 875 Blake Wilbur Dr MC 5151 Stanford, CA 94305 Tel Work (650) 723-6167
- Academic Offices
Alternate Contact Michael Negrette Email Tel Work 650.723.0345Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer
- Medical Oncology
Honors and Awards
- NIH Director's New Innovator Award, NIH (2012)
- Distinguished Scientist Award, Sontag Foundation (2010)
- Basil O' Connor Starter Scholar Award, March of Dimes Foundation (2010-2012)
- Stand Up To Cancer Innovation Research Grant, American Association for Cancer Research (2010-2013)
- Martin D. Abeloff Scholar, V Foundation for Cancer Research (2009-2011)
- Josephine Q. Berry Faculty Scholar in Cancer Research, Stanford University (2009)
Professional Education
| Residency: | Stanford University - CAPS CA (2004) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2008) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2005) |
| Medical Education: | Harvard Medical School MA (2002) |
| Fellowship: | Stanford Hospital, Medical Oncology (2008) |
| Residency: | Stanford Hospital, Internal Medicine (2004) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
We are working to elucidate the biochemical and cell biological principles that govern signaling pathways that sit at the intersection between developmental biology and cancer. Our toolkit combines bulk biochemical techniques, such as cell-free reconstitution, with microscopy using novel optical probes to study the dynamics of signal propagation in cells. We strive to develop novel strategies for the manipulation of these pathways for cancer therapies and applications in regenerative medicine.
Clinical Trials
- Recruiting Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
- Recruiting Molecular Analysis of Thoracic Malignancies
- Not Recruiting Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Publications
- A Smoothened-Evc2 complex transduces the Hedgehog signal at primary cilia. Dev Cell. 2012; (4): 823-35
- Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012; (2): 211-20
- The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. Genes Dev. 2010; (7): 670-82
- Hedgehog signal transduction by smoothened: pharmacological evidence for a two-step activation process. Proceedings of the National Academy of Sciences USA. 2009: 3196-3201
- Lateral transport of Smoothened from the plasma membrane to the membrane of the cilium. J Cell Biol. 2009; (3): 365-74
- Patched1 regulates Hedgehog signaling at the primary cilium. Science. 2007; (5836): 372-376
Help
Trial Administration